Johns Hopkins Bayview says worker uploaded 3,182 patients' data to AI tool
Oct 26, 2026
Listen to this post
read by AI voices ยท all episodesJohns Hopkins Bayview Medical Center is notifying 3,182 patients that their information may have been exposed after an employee uploaded a spreadsheet of patient data to an unapproved outside AI platform, local outlets reported.
The hospital said the upload happened and was discovered on Sept. 21, that the data covered patients treated from May through September and that Social Security and financial account numbers were not included, according to WMAR-2 News. Hopkins said it asked the platform's operator to delete the data and is reinforcing its policy and training on unapproved tools, The Banner reported.
Separately, the Food and Drug Administration cleared two imaging software products, one that measures the aorta on chest CT and one that labels bone on automated musculoskeletal ultrasound, and brain-implant developer Coherence Neuro raised $45 million for investigational cancer devices.
- FYIIncident Oct 23, 2026Johns Hopkins Bayview Medical Center began mailing letters Oct. 22 to 3,182 patients after a staff member uploaded a spreadsheet of their information to an outside AI platform the hospital had not approved for that use, WMAR-2 News reported. The hospital said an internal review found the upload on Sept. 21, the day it happened. The spreadsheet covered patients admitted or treated from May through September and included names, admission and treatment dates, medical record and account numbers, treating department, medications and provider names; the hospital said Social Security numbers and financial account information were not included. The employee deleted the prompt, conversation and document from the tool, and Hopkins asked the tool's parent company to delete the data, according to The Banner, which reported that the tool was not named.Sources: WMAR-2 News, The Banner
- FYIRegulation Oct 23, 2026FDA cleared AVIEW Aorta Metrics, Coreline Soft software that automatically segments the aorta on chest CT images, classifies its anatomical zones and measures diameters in each zone, the company announced Oct. 23. The 510(k) clearance, granted Oct. 16, is the company's 13th, according to the release. The software also produces straightened curved planar reformations, cross-sectional and 3D views and analysis reports. The release included no performance data.
- FYIRegulation Oct 22, 2026RIVANNA said Oct. 22 that FDA cleared BoneEnhance, a machine learning module for its Accuro XV ultrasound system that segments bone and surrounding tissue in each automated volumetric scan and overlays color-coded labels on the B-mode image while leaving the underlying image visible. The company said the module was tested on an independent set of 233 volumetric datasets, comprising 69,900 images from 173 subjects at five sites, against labels from three board-certified radiologists, with label accuracy of 95.1% to 100% per volume; the figures are the company's own. Development was funded through the Biomedical Advanced Research and Development Authority, and an injury-detection module is under investigation, according to the release.Source: RIVANNA release (BioSpace)
- FYIMoney Oct 23, 2026Coherence Neuro raises $45 million for investigational implants that read tumor-linked brain signalsCoherence Neuro, a San Francisco neurotechnology company, raised a $45 million Series A co-led by Founders Fund and the OpenAI Startup Fund, MobiHealthNews reported Oct. 23. The company is developing implants that track electrical signals associated with tumors and use them to guide electrical stimulation; its planned SOMA system pairs a wireless implant with an over-ear wearable and an app. Its devices are investigational and not authorized by FDA, and its work linking neural activity to tumor growth has so far been done in mouse models. A first human study, testing a cortical probe during brain tumor surgery at the Royal Melbourne Hospital in Australia, began in June, and cofounders Ben Woodington and Elise Jenkins wrote that the funding moves the company toward its first long-term human trial in glioblastoma.Source: MobiHealthNews